Audited Financials Results for the year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kapil Cotex Limited (BSE: 512036) filed its audited FY25 results with an unmodified auditor opinion from SPD & Associates. On a standalone basis, total income fell sharply to Rs. 60.36 lakhs from Rs. 200.23 lakhs in FY24 (about 70% decline), and profit after tax dropped to Rs. 48.66 lakhs from Rs. 153.53 lakhs; EPS stood at Rs. 1.50 versus Rs. 3.67. On a consolidated basis, total income was Rs. 743.45 lakhs but the company swung to a loss before tax of Rs. 242.59 lakhs and a loss after tax of Rs. 236.97 lakhs, translating to a loss per share of Rs. 14.19. The drag comes entirely from the newly consolidated subsidiary Skybiotech Life Sciences Pvt Ltd (72.51% acquired in Q2 FY25), which posted revenue of Rs. 725.32 lakhs but a net loss of Rs. 242.86 lakhs. Consolidated operating cash flow turned negative at Rs. -104.25 lakhs, leaving closing cash and equivalents at a negative Rs. -27.23 lakhs versus a positive Rs. 916.24 lakhs opening balance.
Shareholders should note the steep deterioration at the consolidated level: a swing from profit to loss, negative operating cash flow, and a negative closing cash position are red flags driven by the underperforming subsidiary. Standalone remains marginally profitable but with sharply declining revenue, raising questions about the core business momentum and the value of the Skybiotech acquisition.